CAS 36688-78-5: Clindamycin palmitate

Clindamycin palmitate hydrochloride is a semisynthetic antibiotic prodrug, which is derived from the lincomycin family, originally sourced from the bacterium *Streptomyces lincolnensis*. This compound functions through its conversion into the active form, clindamycin, once inside the body. Clindamycin acts by inhibiting bacterial protein synthesis, binding to the 50S subunit of the bacterial ribosome, thereby impeding peptide chain initiation and elongation. The primary application of Clindamycin palmitate hydrochloride is in the treatment of bacterial infections, particularly those caused by anaerobic bacteria and certain aerobic Gram-positive cocci. It is especially effective against *Staphylococcus aureus*, *Streptococcus pneumoniae*, and others susceptible to lincomycin derivatives. This antibiotic is commonly used in pediatric cases, facilitated by its oral formulation that is amenable to administration to children. The medication's efficacy is crucial in treating serious infections such as osteomyelitis, septicemia, and respiratory tract infections, among others, where aerobic and anaerobic bacterial pathogens are implicated.